Grifols SA (GRFS)
7.31
-0.09
(-1.22%)
USD |
NASDAQ |
Sep 18, 16:00
7.295
-0.02
(-0.21%)
After-Hours: 20:00
Grifols Cash from Investing (Quarterly) : -156.60M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -156.60M |
| March 31, 2026 | -138.05M |
| December 31, 2025 | -174.03M |
| September 30, 2025 | -150.58M |
| June 30, 2025 | -123.80M |
| March 31, 2025 | -207.70M |
| December 31, 2024 | -188.58M |
| September 30, 2024 | -210.18M |
| June 30, 2024 | 1.460B |
| March 31, 2024 | -95.68M |
| December 31, 2023 | -147.71M |
| September 30, 2023 | -130.06M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -682.90M |
| December 31, 2020 | -634.64M |
| September 30, 2020 | -97.90M |
| June 30, 2020 | -120.87M |
| Date | Value |
|---|---|
| March 31, 2020 | -124.83M |
| December 31, 2019 | -172.08M |
| September 30, 2019 | 44.45M |
| June 30, 2019 | -198.67M |
| March 31, 2019 | -287.96M |
| December 31, 2018 | -134.54M |
| September 30, 2018 | -389.45M |
| June 30, 2018 | -278.64M |
| March 31, 2018 | -119.78M |
| December 31, 2017 | -186.41M |
| September 30, 2017 | -178.75M |
| June 30, 2017 | -119.65M |
| March 31, 2017 | -1.981B |
| December 31, 2016 | -120.47M |
| September 30, 2016 | -82.63M |
| June 30, 2016 | -255.38M |
| March 31, 2016 | -101.97M |
| December 31, 2015 | -71.57M |
| September 30, 2015 | -90.19M |
| June 30, 2015 | -88.37M |
| March 31, 2015 | -451.94M |
| December 31, 2014 | -70.43M |
| September 30, 2014 | -87.77M |
| June 30, 2014 | -128.83M |
| March 31, 2014 | -1.731B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| argenx SE | -- |
| Evaxion AS | -- |
| Autolus Therapeutics Plc | 68.03M |
| Pharma Mar SA | -37.88M |
| Oryzon Genomics SA | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 265.35M |
| Cash from Financing (Quarterly) | -337.83M |
| Free Cash Flow | 738.77M |
| Free Cash Flow Per Share (Quarterly) | 0.1855 |
| Free Cash Flow to Equity (Quarterly) | 1.529B |
| Free Cash Flow to Firm (Quarterly) | 194.61M |
| Free Cash Flow Yield | 14.85% |